Team:Westminster/Problem

From 2012.igem.org

(Difference between revisions)
 
(17 intermediate revisions not shown)
Line 11: Line 11:
}
}
body {
body {
-
font-family: "HelveticaNeue-Light", "Helvetica Neue Light", "Helvetica Neue", Helvetica, Arial, "Lucida Grande", sans-serif;  
+
font-family: "HelveticaNeue-Light", "Helvetica Neue Light", "Helvetica Neue", Helvetica, Arial, "Lucida Grande", sans-serif;  
font-weight: 300;
font-weight: 300;
-
background: url("http://www.westminsterigem.com/files/theme/body-bg.png") repeat #ffffff;
+
/* background: url("http://www.westminsterigem.com/files/theme/body-bg.png") repeat #ffffff;*/
 +
background-color:#FFF;
color: #666666;
color: #666666;
 +
}
}
-
h1, h2 {
+
h1 {
color: #ff0000;
color: #ff0000;
font-size: 18pt;
font-size: 18pt;
margin-bottom: 0.5em;
margin-bottom: 0.5em;
-
}
+
-
h2 {
+
 
-
font-size: 16pt;
+
-
}
+
-
h3 {
+
-
color: #ff0000;
+
}
}
p {
p {
Line 39: Line 37:
div#content {
div#content {
box-shadow: 0px 0px 17px -4px #666666;
box-shadow: 0px 0px 17px -4px #666666;
 +
padding:0px;
 +
margin-top:0px;
 +
}
}
div#wrapper {
div#wrapper {
position: relative;
position: relative;
-
width: 885px;
+
width: 100%;
font-size: 12pt;
font-size: 12pt;
-
padding: 50px 40px;
 
margin: 0 auto;
margin: 0 auto;
background: #ffffff;
background: #ffffff;
 +
background-attachment: url('https://static.igem.org/mediawiki/2012/2/2e/Bg-tumours.png');
 +
background-repeat: no-repeat;
 +
 +
padding:0px;
 +
margin-top:0px;
 +
top:0px;
 +
}
}
div#header {
div#header {
-
height: 185px;
+
height: 120px;
 +
width: 100%;
 +
background-color:#000;
 +
background: url('https://static.igem.org/mediawiki/2012/2/2e/Bg-tumours.png');
 +
background-repeat: no-repeat;
 +
z-index:10;
 +
position:relative;
 +
top:0px;
 +
left:0px;
}
}
div#header div#logo {
div#header div#logo {
position: relative;
position: relative;
-
width: 400px;
+
width: 260px;
-
height: 125px;
+
right:10px;
-
margin: 0 auto;
+
top:-9px;
 +
float:right;
 +
 
 +
margin-bottom: 0px;
 +
/*
 +
height: 0px;
 +
margin: 0 auto;*/
}
}
-
div#header div#logo {
+
div#header div#logo a {
-
margin-bottom: 20px;
+
float:left;
 +
display:block;
 +
margin-left:10px;
 +
 
}
}
 +
 +
div#navigation {
div#navigation {
-
width: 100%;
+
width: 850px;
-
height: 40px;
+
height: 27px;
-
background: #000000;
+
background:rgba(0,0,0,.5);
 +
float:left;
 +
position:relative;
 +
top:54px;
}
}
ul#navigation-list {
ul#navigation-list {
-
height: 40px;
+
height: 27px;
-
line-height: 40px;
+
line-height: 27px;
-
overflow: hidden;
+
overflow: auto;
}
}
ul#navigation-list > li {
ul#navigation-list > li {
float: left;
float: left;
 +
margin-top:-5px;
}
}
ul#navigation-list > li > ul {
ul#navigation-list > li > ul {
Line 83: Line 113:
}
}
ul#navigation-list > li > ul.submenu li {
ul#navigation-list > li > ul.submenu li {
-
padding: 5px 0px;
+
padding: 2px 0px;
}
}
ul#navigation-list a.navlink {
ul#navigation-list a.navlink {
color: #ffffff;
color: #ffffff;
-
font-weight: bold;
+
font-weight: normal;
display: block;
display: block;
-
padding: 0px 14px;
+
padding: 0px 10px;
text-decoration: none;
text-decoration: none;
}
}
Line 98: Line 128:
div#home-main-image {
div#home-main-image {
text-align: center;
text-align: center;
 +
background-color: #410000;
 +
 +
border-bottom:1px #000 solid;
 +
}
 +
div#the-content {
 +
position:relative;
 +
top:-19px;
 +
}
}
div#home-main-image img {
div#home-main-image img {
-
width: 885px;
+
/*width: 885px;
height: 300px;
height: 300px;
margin-bottom: 20px;
margin-bottom: 20px;
border-radius: 20px;
border-radius: 20px;
 +
*/
}
}
div.text-box {
div.text-box {
Line 110: Line 149:
padding: 15px 20px;
padding: 15px 20px;
border-radius: 10px;
border-radius: 10px;
-
}
+
-
div.three-columns {
+
-
padding-left: 20px;
+
-
overflow: auto;
+
-
}
+
-
div.column, img.column {
+
-
float: left;
+
-
width: 235px;
+
-
margin: 10px 0px 50px 20px;
+
-
border-radius: 10px;
+
}
}
div#footer-box {
div#footer-box {
border-radius: 0 0 5px 5px;
border-radius: 0 0 5px 5px;
 +
}
 +
#bodyContent {
 +
}
 +
#three-column
 +
{
 +
margin:0 auto;
 +
width:850px;
 +
margin-top:50px;
 +
 +
}
 +
 +
.col
 +
{
 +
text-align:justify; float:left; margin:5px;
 +
}
 +
.col h1
 +
{
 +
font-size:14px;
 +
color:#000;
 +
 +
}
 +
/* hide native rubbish*/
 +
#top-section {display:none; position:absolute; left:0px; top:-200px;}
 +
#top-section a { color:#FFF; }
 +
.firstHeading {display:none; position:absolute; left:0px; top:-200px;}
 +
.annoying-gap {
 +
padding:0px;
 +
margin:0px;
 +
line-height:0;
 +
}
 +
 +
#contentSub, #siteSub {display:none;}
 +
 +
#control-btn
 +
{
 +
 +
width: 20px;
 +
height: 20px;
 +
position:absolute;
 +
top:0px;
 +
left:5px;
 +
 +
line-height: 0px;
 +
 +
 +
}
 +
.btn-cog {
 +
background: url('https://static.igem.org/mediawiki/2012/d/d4/Control-panel-sml.png') #000 no-repeat  2px 2px;
 +
}
 +
.btn-close {
 +
background: url('https://static.igem.org/mediawiki/2012/d/d0/Close-btn.png')  #000 no-repeat  2px 2px;
 +
}
 +
.right-menu li a, .left-menu li a {background: none}
 +
 +
#home-main-text {
 +
padding:20px 40px 20px 40px;
 +
text-align: justify;
}
}
</style>
</style>
Line 129: Line 216:
<script type="text/javascript">
<script type="text/javascript">
$('document').ready(function() {
$('document').ready(function() {
-
$('li.submenu-holder').hover(function() {
+
-
$(this).children('ul.submenu').stop(true).fadeIn('slow');
+
// menu
-
}, function() {
+
$('li.submenu-holder').hover(function() {
-
$(this).children('ul.submenu').stop(true).fadeOut('slow');
+
$(this).children('ul.submenu').stop(true).fadeIn('fast');
 +
}, function() {
 +
$(this).children('ul.submenu').stop(true).fadeOut('fast');
 +
});
 +
 
 +
              // hide standard team basics
 +
              $('#top-section').hide();
 +
  $('#bodyContent p:first').addClass("annoying-gap");
 +
 
 +
 +
$('#control-btn').click( function(){
 +
 +
if ($('#control-btn').hasClass("btn-cog"))
 +
{
 +
showTopMenu();
 +
$('#control-btn').animate({left: "-20px"});
 +
$('#control-btn').addClass("btn-close");
 +
$('#control-btn').removeClass("btn-cog");
 +
} else
 +
{
 +
hideTopMenu();
 +
$('#control-btn').animate({left: "0px"});
 +
$('#control-btn').addClass("btn-cog");
 +
$('#control-btn').removeClass("btn-close");
 +
}
});
});
 +
});
});
 +
 +
 +
 +
 +
var $bar;
 +
function hideTopMenu()
 +
{
 +
$bar.slideUp('fast');
 +
 +
}
 +
function showTopMenu()
 +
{
 +
if ($bar==null)
 +
{
 +
$bar = $("#top-section").clone();
 +
$($bar.find("#search-controls")).remove();
 +
$($bar.find("#p-logo")).remove();
 +
$("#wrapper").prepend($bar);
 +
$bar.css("position", "absolute");
 +
$bar.css("top", "0px");
 +
$bar.css("left", "0px");
 +
$bar.css("background", "none");
 +
$bar.css("background", "rgba(0,0,0,.5)");
 +
$bar.css("height", "20px");
 +
$bar.css("border", "none");
 +
$bar.css("z-index", "100");
 +
$bar.css("color", "#000");
 +
 +
 +
}
 +
$bar.slideDown('fast');
 +
 +
$('#control-btn').mouseover( function(){
 +
 +
});
 +
}
</script>
</script>
-
 
</head>
</head>
<body>
<body>
-
 
<div id="wrapper">
<div id="wrapper">
<div id="header">
<div id="header">
-
<div id="logo">
+
  <div id="control-btn" class="btn-cog"></div>
-
<a href="https://2012.igem.org/Team:Westminster">
+
 
-
<img src="https://static.igem.org/mediawiki/2012/1/1e/Westminster-logo.png" alt="iSTEM" title="Back to home!" />
+
-
</a>
+
-
</div><!-- #logo -->
+
<div id="navigation">
<div id="navigation">
<ul id="navigation-list">
<ul id="navigation-list">
<li><a href="https://2012.igem.org/Team:Westminster" class="navlink">Home</a></li>
<li><a href="https://2012.igem.org/Team:Westminster" class="navlink">Home</a></li>
<li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a></li>
<li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a></li>
-
<li><a href="https://igem.org/Team.cgi?year=2012&team_name=Westminster"class="navlink">Team Profile</a></li>
 
<li class="submenu-holder">
<li class="submenu-holder">
-
<a href="https://2012.igem.org/Team:Westminster/Project/Overview"class="navlink active">Project</a>
+
<a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink active">Project</a>
 +
 
<ul class="submenu">
<ul class="submenu">
-
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink active">Overview</a></li>
+
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink">Overview</a></li>
-
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Problem"class="navlink">The Problem</a></li>
+
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Problem"class="navlink active">The Problem</a></li>
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Experiments"class="navlink">Experiments</a></li>
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Experiments"class="navlink">Experiments</a></li>
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Protocols"class="navlink">Protocols</a></li>
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Protocols"class="navlink">Protocols</a></li>
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Results"class="navlink">Results</a></li>
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Results"class="navlink">Results</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li>
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li>
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Journal"class="navlink">Journal</a></li>
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Journal"class="navlink">Journal</a></li>
 +
                           
 +
                 
</ul>
</ul>
</li>
</li>
<li><a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a></li>
<li><a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a></li>
<li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a></li>
<li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a></li>
-
<li><a href="https://2012.igem.org/Team:Westminster/Notebook"class="navlink">Notebook</a></li>
+
<li><a href="https://2012.igem.org/Team:Westminster/Outreach"class="navlink">Outreach</a></li>
-
<li><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li>
+
                    <li><a href="https://2012.igem.org/Team:Westminster/Judging"class="navlink">Judging Criteria</a></li>
 +
 
 +
<li><a href="https://2012.igem.org/Team:Westminster/Attributions"class="navlink">Attributions</a></li>
<li><a href="https://2012.igem.org/Team:Westminster/Attributions"class="navlink">Attributions</a></li>
</ul><!-- #navigation-list -->
</ul><!-- #navigation-list -->
</div><!-- #navigation -->
</div><!-- #navigation -->
 +
            <div id="logo">
 +
                    <a href="http://www.igem.org" title="iGEM homepage"><img src="https://static.igem.org/mediawiki/igem.org/d/dc/Igem-small-white.png" alt="iGEM logo" width="55" height="44" /></a>
 +
<a href="https://2012.igem.org/Team:Westminster">
 +
<img src="https://static.igem.org/mediawiki/2012/a/ae/Logo-white.png" alt="iSTEM - intelligent synthetic tumour eliminating machine" width="172" height="66" title="iSTEM - intelligent synthetic tumour eliminating machine" />
 +
</a>
 +
</div><!-- #logo -->
</div><!-- #header -->
</div><!-- #header -->
-
<div id="the-content">
+
<div id="the-content">
<div id="home-main-image">
<div id="home-main-image">
-
<img src="https://static.igem.org/mediawiki/2012/4/4d/Westminster_team.png" alt="Welcome" title="Welcome to our home!" />
+
<img src="https://static.igem.org/mediawiki/2012/f/f3/Cancerrr.jpg" alt="Welcome" width="965" height="518" title="Welcome to our home!" />
-
</div><!-- #home-main-image -->
+
</div><!-- #home-main-image -->
<div id="home-main-text">
<div id="home-main-text">
<h1>The Problem</h1>
<h1>The Problem</h1>
-
<p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p>
+
<h2>Cancer</h2>
-
<p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p>
+
<p>Cancer remains one of the biggest killers in the world. There are currently about 12.7 million sufferers of cancer around the world, and the number is expected to have doubled by 2030. Around one in four deaths in the UK is caused by cancer, and it is estimated that one in three people will develop a form of cancer in their lifetime. (Cancer Research UK)</p>
-
<h2>Lorem Ipsum</h2>
+
                                <a href="https://2012.igem.org/Team:Westminster">
-
<p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p>
+
<img src="https://static.igem.org/mediawiki/2012/1/18/Cancer_occurrence_rates_edit.png" alt="Occurence rates" title="Occurrence Rates" />
-
<p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p>
+
</a>
 +
<h2>Cancer Recurrence</h2>
 +
<p>Even though cancer treatment and management techniques have improved over the years, cancer recurrence continues to be a problem and source of concern amongst sufferers, their families and medical professionals. The American Cancer Society approximates that about 20% of all breast cancer survivors will develop a recurrent breast cancer. Several reasons have been given for recurrence, one of which is that not all cancer cells are killed during cancer treatment, so these cancer cells are then able to regenerate new tumors. </p>
 +
<h2>Unavailability of Early Diagnostic Tests</h2>
 +
<p>Even with extensive research into cancer and its surrounding phenomena, there is still an unavailability of diagnostic tests that catch some cancers before they start to exhibit serious symptoms. Cancers like bowel and pancreatic cancers can usually not be detected until a patient develops a very big tumor or experiences some bleeding in their stool. It would be ideal to have blood or even non-invasive urine tests that can detect biomarkers for these cancers at the early stages and prevent them from metastasizing. </p>
 +
<h2>Tracking Metastasis</h2>
 +
<p>Even when cancers have been detected in the late stages, medical experts experience problems with detecting areas to which the cancer has spread. </p>
 +
<h2>Current Tools for Cancer Research</h2>
 +
<p>Currently, the Aldefluor assay is commonly used to identify and isolate cancer stem cells.This is a chemical assay used to detect high levels of ALDH expression in cells. Our project aims to build a molecular system which would offer greater sensitivity by targeting distinct ALDH isoforms.   </p>
</div><!-- #home-main-text -->
</div><!-- #home-main-text -->
</div><!-- #the-content -->
</div><!-- #the-content -->
 +
 +
</div><!-- #wrapper -->
</div><!-- #wrapper -->

Latest revision as of 03:52, 27 September 2012

Welcome

The Problem

Cancer

Cancer remains one of the biggest killers in the world. There are currently about 12.7 million sufferers of cancer around the world, and the number is expected to have doubled by 2030. Around one in four deaths in the UK is caused by cancer, and it is estimated that one in three people will develop a form of cancer in their lifetime. (Cancer Research UK)

Occurence rates

Cancer Recurrence

Even though cancer treatment and management techniques have improved over the years, cancer recurrence continues to be a problem and source of concern amongst sufferers, their families and medical professionals. The American Cancer Society approximates that about 20% of all breast cancer survivors will develop a recurrent breast cancer. Several reasons have been given for recurrence, one of which is that not all cancer cells are killed during cancer treatment, so these cancer cells are then able to regenerate new tumors.

Unavailability of Early Diagnostic Tests

Even with extensive research into cancer and its surrounding phenomena, there is still an unavailability of diagnostic tests that catch some cancers before they start to exhibit serious symptoms. Cancers like bowel and pancreatic cancers can usually not be detected until a patient develops a very big tumor or experiences some bleeding in their stool. It would be ideal to have blood or even non-invasive urine tests that can detect biomarkers for these cancers at the early stages and prevent them from metastasizing.

Tracking Metastasis

Even when cancers have been detected in the late stages, medical experts experience problems with detecting areas to which the cancer has spread.

Current Tools for Cancer Research

Currently, the Aldefluor assay is commonly used to identify and isolate cancer stem cells.This is a chemical assay used to detect high levels of ALDH expression in cells. Our project aims to build a molecular system which would offer greater sensitivity by targeting distinct ALDH isoforms.

Retrieved from "http://2012.igem.org/Team:Westminster/Problem"